Moderna Seeks FDA Nod for New JN.1 COVID-19 Variant Vaccine

Published 2 hours agoMRNA

Moderna Seeks FDA Nod for New JN.1 COVID-19 Variant Vaccine

Moderna has officially submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for its latest COVID-19 vaccine. This updated vaccine is specifically designed to target the JN.1 variant of SARS-CoV-2, which is currently prevalent in the U.S. According to Reuters, this move aligns with the FDA's recommendation to update COVID-19 vaccines to a monovalent JN.1 composition for the upcoming 2024-2025 season.

Essential details include Moderna's plan to ramp up production of the new vaccine, with distribution slated for August in preparation for the next vaccination season. Preliminary clinical studies report a strong immune response against the JN.1 variant, although typical side effects such as pain at the injection site, headaches, fatigue, muscle pain, and chills have been observed in test subjects.

In light of this development, Moderna's strategy reflects a proactive approach to addressing evolving COVID-19 variants. The company has conveyed a sense of readiness for vaccine distribution, which has positively influenced its market trajectory, with investors showing confidence as indicated by a modest stock price increase. Currently, Moderna's stock is priced at $26.27, experiencing a slight dip from its previous close.

Share this article

Twitter Facebook LinkedIn

Recent Articles

TotalEnergies Responds to Human Rights Abuse Allegations in Africa

TotalEnergies Responds to Human Rights Abuse Allegations in Africa

43 minutes agoTTE

TotalEnergies is under scrutiny for alleged human rights abuses connected to its projects in Africa, specifically the East African Crude Oil Pipeline (EACOP) in Uganda and the Mozambique LNG project. The company's CEO, Patrick Pouyanné, has publicly addressed these allegations, emphasizing TotalEnergies' commitment to human rights practices. The EACOP project has faced serious accusations from Just Finance International, which claims that TotalEnergies is involved in forced evictions and other abuses by Ugandan security forces at the Kingfisher oil site. In response, TotalEnergies has categorically denied any involvement, maintaining a zero-tolerance policy for such abuses and stating their cooperation with Ugandan authorities. Additionally, Reuters reported that Germany's Union Investment has withdrawn TotalEnergies from its sustainability funds and demanded an independent audit of the situation. Regarding the Mozambique LNG project, media claims have emerged about detainments and alleged killings by Mozambican soldiers on site. TotalEnergies insists it was unaware of these incidents prior to media contact and has expressed its readiness to cooperate with the ongoing official investigations by Mozambican authorities. The company reiterates its dedication to human rights and to working with local authorities to resolve these claims.

Prothena Stock Tumbles as Phase 3 Study on Birtamimab Fails

Prothena Stock Tumbles as Phase 3 Study on Birtamimab Fails

1 hours agoPRTA

Prothena Corporation faced a major setback as its stock plummeted by roughly 63% following the unsuccessful results of its Phase 3 VITAL Amyloidosis Study. The trial, assessing the efficacy of birtamimab (NEOD001) for treating AL amyloidosis, was terminated early in 2018 due to a futility analysis indicating it would not meet its primary goals, according to Gen Eng News. The final results from the study showed a hazard ratio of 0.835 for the combined primary endpoint, which included metrics such as time to all-cause mortality or cardiac hospitalization. This ratio, with a 95% confidence interval ranging from 0.5799 to 1.2011 and a p-value of 0.3300, verified the earlier futility analysis, as reported by GlobeNewswire. Additionally, none of the secondary endpoints reached statistical significance across the study population, further underscoring the trial's disappointing findings. Despite these outcomes, a post hoc analysis indicated a potential survival advantage for patients with Mayo Stage IV AL amyloidosis, showing a hazard ratio of 0.544. However, this was not statistically significant. These results raise important questions regarding the future prospects of birtamimab as an effective treatment avenue for AL amyloidosis, leaving Prothena to reassess its strategic direction.

CrowdStrike's Revenue Growth Impresses Despite Challenges

CrowdStrike's Revenue Growth Impresses Despite Challenges

1 hours agoCRWD

S&P Global Ratings has not recently revised CrowdStrike Holdings Inc.'s outlook to positive, maintaining a 'BB+' rating. The latest comprehensive report from S&P dates back to December 16, 2024, highlighting that CrowdStrike's performance exceeded expectations. The company reported annual recurring revenue surpassing $4 billion, alongside total revenue topping $1 billion for the first time. In an earlier incident in July 2024, CrowdStrike faced a significant service outage caused by a software update issue, leading to disruptions. However, the cybersecurity firm bounced back quickly, introducing customer commitment packages and posting strong growth in annual recurring revenue. Throughout this period, JPMorgan maintained an optimistic stance on CrowdStrike, reaffirming an Overweight rating and raising the price target to $369 owing to the platform's robust performance and revenue growth. Beyond these financial results, CrowdStrike marked a notable achievement in June 2024 by joining the S&P 500 Index, becoming the fastest cybersecurity firm to reach this milestone. This move underscored its standing and innovation within the industry. Although there have been numerous positive developments, there's no verified information at present about S&P revising CrowdStrike's outlook to positive.

United Airlines Strikes Tentative Deal with Flight Attendants

United Airlines Strikes Tentative Deal with Flight Attendants

United Airlines and its flight attendants, represented by the Association of Flight Attendants-CWA (AFA), have reached a tentative agreement on a new contract. The agreement is noteworthy for its industry-leading compensation, offering flight attendants a significant financial boost with expected gains of 40% in the first year, according to Reuters. This breakthrough comes after the flight attendants had authorized a strike, emphasizing the necessity for a resolution. The proposed contract also includes retroactive pay addressing compensation for time spent on the ground and other work-related hours, which was a crucial concern. Additionally, the deal covers improved work rules and enhanced scheduling flexibility, aiming for a better work-life balance for the workers. These improvements demonstrate a comprehensive effort to better the terms of employment for the flight attendants. Union leadership is set to review the contract next week. If approved, it will advance to a membership ratification vote. This progression follows a period since 2020 without a raise for United Airlines' flight attendants, marking a potential end to lengthy negotiations aimed at securing improved compensation and working conditions.